Phio Pharmaceuticals Corp. — Director's Dealing 2026

Jan 2, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Phio Pharmaceuticals Corp. (PHIO)
CIK: 0001533040
Period of Report: 2025-12-31

Reporting Person: Bitterman Robert J (Director, Chairman, Pres. & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-12-31	Common Stock, $.0001 par value	P	5000	$1.03	Acquired	291421	Direct

Footnotes

F1: Includes shares of common stock underlying unvested restricted stock units.